Literature DB >> 18255119

In vitro binding of simian immunodeficiency virus matrix protein to the cytoplasmic domain of the envelope glycoprotein.

Julieta M Manrique1, José L Affranchino, Silvia A González.   

Abstract

Incorporation of the envelope (Env) glycoprotein into budding virions is a key step in the replication cycle of lentiviruses. Previously, we provided genetic and biochemical evidence indicating that Env packaging into simian immunodeficiency virus (SIV) particles is mediated by the association of the Env cytoplasmic domain (CD) with the matrix (MA) domain of Gag. In this study, we developed an in vitro binding assay that, based on recombinant proteins expressed in bacteria, allowed us to demonstrate the physical interaction between the SIV Env CD and the MA in the absence of other viral or cellular proteins. We show that this association is blocked by mutations in each of the interacting domains that have been reported to interfere in vivo with the incorporation of Env into SIV virions. Moreover, we determined that the binding of SIV MA to the Env CD is saturable with a dissociation constant of 7x10(-7) M. Interestingly, the SIV MA is capable of specifically interacting in vitro with the human immunodeficiency virus type 1 Env CD, but not with that of the distantly related feline immunodeficiency virus. Our results strongly support the notion that the association between the SIV MA and Env CD plays a central role in the process of SIV Env incorporation into Gag-made particles.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18255119     DOI: 10.1016/j.virol.2008.01.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Retrovirus glycoprotein functionality requires proper alignment of the ectodomain and the membrane-proximal cytoplasmic tail.

Authors:  Sanath Kumar Janaka; Devon A Gregory; Marc C Johnson
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

2.  Multiple Gag domains contribute to selective recruitment of murine leukemia virus (MLV) Env to MLV virions.

Authors:  Devon A Gregory; Terri D Lyddon; Marc C Johnson
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

3.  The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  Cell Host Microbe       Date:  2012-02-16       Impact factor: 21.023

Review 4.  Mechanisms for Env glycoprotein acquisition by retroviruses.

Authors:  Marc C Johnson
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-22       Impact factor: 2.205

5.  Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Peter Y Mercredi; Sampson K Kyere; Justin Donlan; Tsutomu Murakami; Michael F Summers; Simon Cocklin; Eric O Freed
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

Review 6.  The role of matrix in HIV-1 envelope glycoprotein incorporation.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Trends Microbiol       Date:  2014-06-02       Impact factor: 17.079

Review 7.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  Retroviral env glycoprotein trafficking and incorporation into virions.

Authors:  Tsutomu Murakami
Journal:  Mol Biol Int       Date:  2012-07-02

9.  Rab11-FIP1C and Rab14 direct plasma membrane sorting and particle incorporation of the HIV-1 envelope glycoprotein complex.

Authors:  Mingli Qi; Janice A Williams; Hin Chu; Xuemin Chen; Jaang-Jiun Wang; Lingmei Ding; Ehiole Akhirome; Xiaoyun Wen; Lynne A Lapierre; James R Goldenring; Paul Spearman
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

10.  Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure.

Authors:  Philip R Tedbury; Sherimay D Ablan; Eric O Freed
Journal:  PLoS Pathog       Date:  2013-11-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.